HOME >> MEDICINE >> NEWS
Acrux and Oreganon further expand their collaboration

Drug delivery company Acrux (ASX: ACR), announced today that it has signed a further agreement with Organon, the human healthcare business unit of Akzo Nobel, expanding the two parties' collaboration. This follows the recently announced deal under which Organon and Acrux will develop and commercialise contraceptives, delivered through the skin using Acrux's unique spray technology.

Under the new agreement, Organon has licensed Acrux's technology for delivery of a non-hormone, proprietary Organon drug, for a substantial global women's health market.

"The expansion of our important relationship with Organon, one of the leading innovators in women's health, confirms that our unique spray technology has even broader potential" said Acrux CEO Richard Treagus.

"This adds a new, non-hormone drug to our pipeline and demonstrates the potential to use the technology to deliver drugs owned by our partners", he added.

Organon executive vice president, Research and Development, David Nicholson commented "The Acrux technology is an appealing method of delivering medication, with the potential to extend the choices available for women to fit their needs and lifestyle."

Acrux will be responsible for developing formulations of the undisclosed compound and upon successful completion; Organon will undertake and fund all clinical trials, regulatory submissions, manufacturing and commercialization efforts.

Acrux may receive payments totalling US$12 million as development and regulatory milestones are achieved.

Acrux will also earn royalties on worldwide sales of the product.


'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-383-790-100
Research Australia
6-Mar-2007


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Stomach cancer rate set to fall further 25 percent over next decade
8. High tech help to prevent further heart disease
9. Altered activity in receptor pair points to further complexity in schizophrenia pathology
10. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
11. Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acrux and Oreganon further expand their collaboration

(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... The Jerry ... at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over ... raised more than $13.5 million for programs and services designed to support patients and ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the Massachusetts-based charity ... (FSHD), will be the beneficiary of a collection of fundraising events this fall. From ... of the FSH Society and further FSHD research. , The list of ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring Ed ... on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, qualification, ...
(Date:9/1/2015)... York, NY (PRWEB) , ... September 01, 2015 ... ... that, to date, more than 1,500 investor-families have received permanent green cards (I-829 ... EB-5 projects. , The I-829 petition is the final step of the EB-5 ...
Breaking Medicine News(10 mins):Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2
(Date:9/1/2015)... , Sept. 1, 2015  Abbott (NYSE: ABT ... a multi-center, randomized trial comparing the safety and effectiveness ... ® , Abbott,s market-leading, permanent drug eluting stent. ... Japan and enrolled 400 people with ... disease. The results will be featured at a late-breaking ...
(Date:9/1/2015)... , Sept. 1, 2015  Valeant Pharmaceuticals International, ... today announced that its affiliate has entered into ... was granted an exclusive license to develop and ... IL-17 receptor monoclonal antibody in development for patients ... the agreement, Valeant will hold the exclusive rights ...
(Date:8/31/2015)... Pepperl+Fuchs, a world leader in process ... leading provider of HART protocol devices. The move ... its integrated solutions offerings and strengthen its position ... are pleased to add the MACTek WirelessHART product ... Bolin , Pepperl+Fuchs, executive vice president of the ...
Breaking Medicine Technology:Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 2Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 3Abbott Announces Positive Results of Its Naturally Dissolving Stent from ABSORB Japan Study 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
Cached News: